HealthPhoto: HT WorldModerna's Cancer Vaccine Shows Promise but Stock Faces Volatility
Moderna's cancer vaccine passed a major trial, reducing melanoma recurrence or death risk by 42% when combined with Merck's Keytruda in 1,137 patients. Despite this success, Moderna's stock remains volatile, having surged nearly fourfold after initial trial news but dropped 20% following detailed data release. The vaccine's broader impact beyond melanoma remains uncertain, contributing to stock price fluctuations.
HT World·



